Things have gone from bad to worse for the blood-testing startup Theranos, which is now under both a criminal investigation as well as a probe by the U.S. Securities and Exchange Commission, according to sources who spoke with the Wall Street Journal. A once-beloved “unicorn” of the Silicon Valley startup scene, Theranos was worth as much as $9 billion only a few months ago, but has faced a precipitous fall from grace since last October when a Wall Street Journal report raised serious questions about the effectiveness of its tests.DH
collectionsInnovation FestivalCurrent Issue
World Changing Ideas
New workplaces, new food sources, new medicine--even an entirely new economic system.
The major tech ecosystems that battle for our attention and dollars.
What’s next for hardware, software, and services.
The brave new world of automation, from AI to drones.
How our urban centers are building toward the future.
Most Creative People
See members of our Most Creative People in Business community: leaders who are shaping the future of business in creative ways.
An award-winning team of journalists, designers, and videographers who tell brand stories through Fast Company's distinctive lens.